The company has formalized an existing relationship by acquiring Pharmatech, hoping to directly integrate the firm's "right on time" trial matching service with its own molecular testing.
Tissue-agnostic drug development approaches have their own set of scientific and financial considerations, but some drugmakers are taking on those challenges.
The firms will integrate Caris' molecular profiling services with Pharmatech's clinical trials recruitment and network services to further precision medicine.
A busy second day of the JP Morgan conference saw Thermo Fisher's Marc Casper discuss the firm's R&D focus and Exact Sciences' Kevin Conroy discuss plans for Cologuard sales growth.
The company will use the proceeds in part to develop its Next Generation Profiling offering to analyze cancer genomes, transcriptomes, and proteomes with clinical outcome data.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
